Rosiglitazone prevents acute pancreatitis through inhibiting microRNA‑26a expression

Chen,Yan; Xiang,Wei; Li,Xiang; Wang,Daming; Qian,Chunyan

doi:10.3892/etm.2019.7711

Rosiglitazone prevents acute pancreatitis through inhibiting microRNA‑26a expression

Authors:
- Yan Chen
- Wei Xiang
- Xiang Li
- Daming Wang
- Chunyan Qian
View Affiliations

Affiliations: Department of Emergency, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Drug Clinical Trial Institution, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: June 26, 2019 https://doi.org/10.3892/etm.2019.7711
Pages: 1246-1252
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the regulatory effect of rosiglitazone on the progression of acute pancreatitis (AP) and pancreas injury, and the underlying mechanism. An AP rat model was established using caerulein and validated by detection of amylase, lipase, tumor necrosis factor‑α (TNF‑α), interleukin‑6 (IL‑6) and transforming growth factor‑β (TGF‑β) serum levels. Pancreatic injury was assessed by pathological examination. The expression levels of microRNA (miR)‑26a in AP rats and AR42J cells were analyzed using reverse transcription‑quantitative PCR (RT‑qPCR). Luciferase reporter gene assay was applied for detecting whether miR‑26a bound to the target gene phosphatase and tensin homolog (PTEN). The regulatory effect of rosiglitazone on the PI3K/AKT signaling pathway was analyzed by western blot analysis. Results demonstrated that establishment of an AP model was successful with severe pancreas injury and classic AP phenotypes observed in rats. Increased serum expression of amylase, lipase, TNF‑α, IL‑6 and TGF‑β were observed in AP rats. Rosiglitazone pretreatment prevented AP progression through suppression of miR‑26a expression via binding to and degrading PTEN. Western blot analysis demonstrated that rosiglitazone blocked the PI3K/AKT signaling pathway through PTEN. In conclusion, it was determined that rosiglitazone prevented AP by downregulating miR‑26a via the PI3K/AKT signaling pathway.

View Figures

View References

1	Banks PA and Freeman ML; Practice Parameters Committee of the American College of Gastroenterology, : Practice guidelines in acute pancreatitis. Am J Gastroenterol. 101:2379–2400. 2006. View Article : Google Scholar : PubMed/NCBI
2	Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG and Vege SS; AcutePancreatitis Classification Working Group, : Classification of acute pancreatitis-2012: Revision of the Atlanta classification and definitions by international consensus. Gut. 62:102–111. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kylanpaa ML, Repo H and Puolakkainen PA: Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol. 16:2867–2872. 2010. View Article : Google Scholar : PubMed/NCBI
4	Petrov M: Nutrition, inflammation, and acute pancreatitis. ISRN Inflamm. 2013:3414102013. View Article : Google Scholar : PubMed/NCBI
5	Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, et al: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 355:2427–2443. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fryer LG, Parbu-Patel A and Carling D: The anti-diabetic drugs rosiglitazone and metformin stimulate amp-activated protein kinase through distinct signaling pathways. J Biol Chem. 277:25226–25232. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ramakers JD, Verstege MI, Thuijls G, Te VA, Mensink RP and Plat J: The ppargamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol. 27:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ji XX, Ji XJ, Li QQ, Lu XX and Luo L: Rosiglitazone reduces apoptosis and inflammation in lipopolysaccharide-induced human umbilical vein endothelial cells. Med Sci Monit. 24:6200–6207. 2018. View Article : Google Scholar : PubMed/NCBI
9	Ding F, Qiu J, Li Q, Hu J, Song C, Han C, He H and Wang J: Effects of rosiglitazone on proliferation and differentiation of duck preadipocytes. In Vitro Cell Dev Biol Anim. 52:174–181. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cheng Y, Li S, Wang M, Cheng C and Liu R: Peroxisome proliferator activated receptor gamma (PPARgamma) agonist rosiglitazone ameliorate airway inflammation by inhibiting toll-like receptor 2 (TLR2)/Nod-like receptor with pyrin domain containing 3 (NLRP3) inflammatory corpuscle activation in asthmatic Mice. Med Sci Monit. 24:9045–9053. 2018. View Article : Google Scholar : PubMed/NCBI
11	Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M and Harats D: Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab. 5:45–50. 2003. View Article : Google Scholar : PubMed/NCBI
12	Hassumi MY, Silva-Filho VJ, Campos-Junior JC, Vieira SM, Cunha FQ, Alves PM, Alves JB, Kawai T, Gonçalves RB and Napimoga MH: PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol. 9:1150–1158. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lin S and Gregory RI: Microrna biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
14	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: Microrna signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
15	Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP: Mir-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of ezh2. Cancer Res. 71:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kwon Y, Kim Y, Eom S, Kim M, Park D, Kim H, Noh K, Lee H, Lee YS, Choe J, et al: Microrna-26a/-26b-cox-2-mip-2 loop regulates allergic inflammation and allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells. J Biol Chem. 290:14245–14266. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kumar A, Bhatia HS, de Oliveira AC and Fiebich BL: Microrna-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia. J Neurochem. 135:1189–1202. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Georgescu MM: PTEN tumor suppressor network in PI3K-AKT pathway control. Genes Cancer. 1:1170–1177. 2010. View Article : Google Scholar : PubMed/NCBI
20	Chen L, Yu CX, Song B, Cai W, Liu C and Guan QB: Free fatty acids mediates human umbilical vein endothelial cells inflammation through toll-like receptor-4. Eur Rev Med Pharmacol Sci. 22:2421–2431. 2018.PubMed/NCBI
21	Sah RP, Garg P and Saluja AK: Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol. 28:507–515. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wu XQ, Dai Y, Yang Y, Huang C, Meng XM, Wu BM and Li J: Emerging role of microRNAS in regulating macrophage activation and polarization in immune response and inflammation. Immunology. 148:237–248. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yang X, Guan Y, Tian S, Wang Y, Sun K and Chen Q: Mechanical and IL-1β responsive miR-365 contributes to osteoarthritis development by targeting histone deacetylase 4. Int J Mol Sci. 17:4362016. View Article : Google Scholar : PubMed/NCBI
24	Wang H, Bei Y, Shen S, Huang P, Shi J, Zhang J, Sun Q, Chen Y, Yang Y, Xu T, et al: miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2. J Mol Cell Cardiol. 94:43–53. 2016. View Article : Google Scholar : PubMed/NCBI
25	Sharma AR, Sharma G, Lee SS and Chakraborty C: Mirna-regulated key components of cytokine signaling pathways and inflammation in rheumatoid arthritis. Med Res Rev. 36:425–439. 2016. View Article : Google Scholar : PubMed/NCBI
26	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
27	Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M, et al: T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 14:523–534. 2001. View Article : Google Scholar : PubMed/NCBI
28	Paez J and Sellers WR: PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res. 115:145–167. 2003. View Article : Google Scholar : PubMed/NCBI
29	Weichhart T and Saemann MD: The PI3K/AKT/MTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis. 67 (Suppl 3):iii70–iii74. 2008. View Article : Google Scholar : PubMed/NCBI